THE PROFILE OF MICRORNA EXPRESSION IN LIVER IN CHRONIC HEPATITIS C PATIENTS AND THEIR ASSOCIATION WITH CLINICAL PARAMETERS

DOI: https://doi.org/None

Bovt P.A., Vishnevskaya T.V., Nurmukhametova E.A., Blokhina N.P., Deryabin P.G., Samokhvalov E.I., Kolobukhina L.V., Khlopova I.N., Kelly E.I., Malyshev N.A., AlkhovskyS.V.

Introduction. Hepatitis C virus (HCV) is a major risk factor for chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Molecular mechanisms of fibrogenesis are associated with the activation or inhibition of signaling pathways, which are controlling by microRNAs (miRNAs). miRNAs are small non-coding RNAs that regulate gene expression by means of suppressing translation and/or mRNA degradation. Aberrant miRNA expression is related with development of multiple pathological processes, including liver diseases. The aim of the study. Experimental evaluation of miRNA expression in liver biopsies from chronic hepatitis C (CHC) patients and the analysis of the interrelationship with clinical and morphological parameters of the disease. Methods. MiRNA libraries from 12 CHСpatientswere sequenced with the use of the system«MiSeq Illumina» for the genetic analysis. Obtained results were treatedwith the aid of CLC Genomics Workbench 7.0 software. Results. Levels of the expression of 1104 miRNA were detected. The performed statistical analysis revealed the interrelationship between miRNAs expression levels and clinical and morphological data: the degree of histological activity, a stage of fibrosis and HCV genotype. The expression level of miR-21, miR-143, miR-200 and other miRNAscorrelated with the progression of liver fibrosis. Conclusion. The findings indicate to the alteration of the microRNA expression in the progression of liver fibrosis in CHC patients. It can serve as an auxiliary diagnostic and prognostic tool in HCV infection.
Keywords: 
hepatitis C, microRNA, fibrosis, signal pathways
Список литературы: 
  1. http://www.who.int/mediacentre/factsheets/fs164/ru/
  2. Roy S., Benz F., Luedde T., Rodeburg C. The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis. Hepatobiliary Surg. Nutr. 2015; 4 (1): 24–33.
  3. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005; 115 (2): 209–18.
  4. Pellicoro A., Ramachandran P., Iredale J.P., Fallowfield J.A. Liver fibrosis and repair:immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 2014; 14: 181–94.
  5. He Y., Huang C., Zhang S., Sun X., Long X., Li J. The potential of microRNAs in liver fibrosis. Cellular signaling. 2012; 24: 2268–72.
  6. Lee S.N., Kim J.H., Lee S. Rhe role of microRNAs in hepatitis C virus replication and related liver disease. J. of Microbiol. 2014; 52 (6): 445–51.
  7. Murakami Y., Tanaka M., Toyoda H., Hayashi K., Kuroda M., Tajima A., Shimotohno K. Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med. Genomics. 2010; 3: 48.
  8. Desmet V.J., Gerber M., Hoofnagle J.H. et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994; 19: 1513–20.
  9. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996; 24: 289–93.
  10. Shah N., Nelson J.E., Kowdley K.V. MicroRNAs in liver disease: bench to bedside. J. of Clin. and Exp. Hepat. 2013; 3 (3): 231–42.
  11. Shrivastava S., Mukherjee A., Ray R.B. Hepatitis C virus infection, microRNA and liver disease progression. World J. Hepatol. 2013; 5 (9): 479–86.
  12. Banaudha K., Kaliszewski M., Korolnek L., Florea L., Yeung M.L., Jeang K.T., Kumar A. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology. 2011; 53: 53–61.
  13. Szabo G., BalaS. MicroRNAs in liver disease. Nat. Rev. Gastroenterol. Hepatol. 2013; 10 (9): 542–52.
  14. Vettori S., Gay S., Distler O. Role of MicroRNAs in Fibrosis. Open Rheumatol. 2012; 6: 130–9.
  15. Marquez R.T., Bandyopadhyay S., Wendlandt E.B., Keck K., Hoffer B.A., Icardi M.S., Christensen R.N., Schmidt W.N., McCaffrey A.P. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab. Invest. 2010; 90 (12): 1727–36.
  16. Men R., Wen M., Dan X., Wang., Liu X., Y L. Inhibition of Kruppel-like factor-4 (KLF4) by miR-143/145 promotes activation of hepatic stellate cells. United European Gastroenterology J. 2014; 2 (1).
  17. Murakami Y., Toyoda H., Tanaka M., Kuroda M., Harada Y., Matsuda F., Tajima A., Kosaka N., Ochiya T., Shimotohno K. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS ONE. 2011; 6 (1): e16081.
  18. Sun X., He Y., Ma T.T., Huang C., Zhang L., Li J. Participation of miR-200a in TGF-β1-mediated hepatic stellate cell activation. Mol. Cell. Biochem. 2014; 388 (1–2): 11–23.